{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:33:53Z","timestamp":1791851633179,"version":"4.3.4"},"reference-count":80,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.clinthera.2024.11.015","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T20:19:11Z","timestamp":1734725951000},"page":"158-167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Recent Advances in Individualized Clinical Strategies for Polycystic Ovary Syndrome: Evidence From Clinical Trials and Emerging Pharmacotherapies"],"prefix":"10.1016","volume":"47","author":[{"given":"Murali Krishna","family":"Moka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damal Kandadai","family":"Sriram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1565-3824","authenticated-orcid":false,"given":"Melvin","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.11.015_bib0001","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.51321","article-title":"The invisible struggle: the psychosocial aspects of polycystic ovary syndrome","author":"Dewani","year":"2023","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.clinthera.2024.11.015_bib0002","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12902-022-01208-y","article-title":"Lifestyle management in polycystic ovary syndrome \u2013 beyond diet and physical activity","volume":"23","author":"Cowan","year":"2023","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"10.1016\/j.clinthera.2024.11.015_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/er.2008-0030","article-title":"Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review","volume":"30","author":"Palomba","year":"2009","journal-title":"Endocr Rev"},{"key":"10.1016\/j.clinthera.2024.11.015_bib0004","doi-asserted-by":"crossref","first-page":"k2477","DOI":"10.1136\/bmj.k2477","article-title":"Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study","author":"Given","year":"2018","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.clinthera.2024.11.015_bib0005","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/aogs.14878","article-title":"Metformin use in pregnancy: What about long-term effects in offspring?","volume":"103","author":"Toft","year":"2024","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"4","key":"10.1016\/j.clinthera.2024.11.015_bib0006","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3390\/ph17040478","article-title":"View on metformin: antidiabetic and pleiotropic effects, pharmacokinetics, side effects, and sex-related differences","volume":"17","author":"Froldi","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.clinthera.2024.11.015_bib0007","doi-asserted-by":"crossref","DOI":"10.1177\/2042018821989238","article-title":"The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence","volume":"12","author":"Abdalla","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.clinthera.2024.11.015_bib0008","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.fertnstert.2023.11.013","article-title":"Prevention of moderate and severe ovarian hyperstimulation syndrome: a guideline","volume":"121","year":"2024","journal-title":"Fertil Steril"},{"issue":"10","key":"10.1016\/j.clinthera.2024.11.015_bib0009","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.3390\/diagnostics12102555","article-title":"Need to introduce the finding of obesity or normal body weight in the current diagnostic criteria and in the classification of PCOS","volume":"12","author":"Carmina","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.clinthera.2024.11.015_bib0010","doi-asserted-by":"crossref","first-page":"11983","DOI":"10.53730\/ijhs.v6nS3.9225","article-title":"Survey based on classification of PCOS using gene expression","volume":"6","author":"Poorani","year":"2022","journal-title":"Int J Health Sci (Qassim)"},{"key":"10.1016\/j.clinthera.2024.11.015_bib0011","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ics.2005.01.002","article-title":"PCOS: Backgrounds, evidence and problems in diagnosing the syndrome","volume":"1279","author":"Laven","year":"2005","journal-title":"Int Congr Ser"},{"issue":"Supplement_1","key":"10.1016\/j.clinthera.2024.11.015_bib0012","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/humrep\/dead093.114","article-title":"O-095 different phenotypes of PCOS: Implications to clinical practice","volume":"38","author":"Franks","year":"2023","journal-title":"Hum Reprod"},{"key":"10.1016\/j.clinthera.2024.11.015_bib0059","doi-asserted-by":"crossref","first-page":"1","DOI":"10.54133\/ajms.v2i.53","article-title":"Impact of vitamin D deficiency on the pathogenesis of polycystic ovary syndrome","volume":"2","author":"Majid Raheem","year":"2022","journal-title":"Al-Rafidain J Med Sci"},{"issue":"2","key":"10.1016\/j.clinthera.2024.11.015_bib0060","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3831\/KPI.2023.26.2.105","article-title":"A review on acupuncture efficiency in human polycystic ovary\/ovarian syndrome","volume":"26","author":"Oliveira","year":"2023","journal-title":"J Pharmacopuncture"},{"key":"10.1016\/j.clinthera.2024.11.015_bib0061","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1024844","article-title":"Cardiovascular autonomic modulation differences between moderate-intensity continuous and high-intensity interval aerobic training in women with PCOS: a randomized trial","volume":"13","author":"Philbois","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"10.1016\/j.clinthera.2024.11.015_bib0062","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/humrep\/deac047","article-title":"High-intensity training elicits greater improvements in cardio-metabolic and reproductive outcomes than moderate-intensity training in women with polycystic ovary syndrome: a randomized clinical trial","volume":"37","author":"Patten","year":"2022","journal-title":"Hum Reprod"},{"issue":"7","key":"10.1016\/j.clinthera.2024.11.015_bib0063","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1097\/MS9.0000000000000879","article-title":"Vitamin D and polycystic ovary syndrome (PCOS): a review","volume":"85","author":"Mohan","year":"2023","journal-title":"Ann Med Surg"},{"issue":"2","key":"10.1016\/j.clinthera.2024.11.015_bib0064","doi-asserted-by":"crossref","first-page":"190","DOI":"10.12775\/JEHS.2023.13.02.027","article-title":"Vitamin D supplementation in polycystic ovary syndrome","volume":"13","author":"Grzywna","year":"2022","journal-title":"J Educ Heal Sport"},{"issue":"9","key":"10.1016\/j.clinthera.2024.11.015_bib0065","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1111\/jog.15727","article-title":"Effect of vitamin D supplementation on hormones and menstrual cycle regularization in polycystic ovary syndrome women: a systemic review and meta-analysis","volume":"49","author":"Han","year":"2023","journal-title":"J Obstet Gynaecol Res"},{"issue":"2","key":"10.1016\/j.clinthera.2024.11.015_bib0066","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/ijgo.14568","article-title":"Role of C-type natriuretic peptide in polycystic ovary syndrome","volume":"161","author":"\u00d6zay","year":"2023","journal-title":"Int J Gynecol Obstet"},{"issue":"9","key":"10.1016\/j.clinthera.2024.11.015_bib0067","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1042\/CS20171491","article-title":"C-type natriuretic peptide: a link between hyperandrogenism and anovulation in a mouse model of polycystic ovary syndrome","volume":"132","author":"Reis","year":"2018","journal-title":"Clin Sci"},{"issue":"8","key":"10.1016\/j.clinthera.2024.11.015_bib0031","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.3390\/ijms23084334","article-title":"The role of Glp-1 receptor agonists in insulin resistance with concomitant obesity treatment in polycystic ovary syndrome","volume":"23","author":"Bednarz","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.clinthera.2024.11.015_bib0068","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1042\/CS20171394","article-title":"High level of C-type natriuretic peptide induced by hyperandrogen-mediated anovulation in polycystic ovary syndrome mice","volume":"132","author":"Wang","year":"2018","journal-title":"Clin Sci"},{"issue":"7","key":"10.1016\/j.clinthera.2024.11.015_bib0069","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1210\/me.2012-1027","article-title":"C-type natriuretic peptide stimulates ovarian follicle development","volume":"26","author":"Sato","year":"2012","journal-title":"Mol Endocrinol"},{"issue":"4","key":"10.1016\/j.clinthera.2024.11.015_bib0070","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2217\/bmm.10.67","article-title":"C-type natriuretic-derived peptides as biomarkers in human disease","volume":"4","author":"Lippert","year":"2010","journal-title":"Biomark Med"},{"key":"10.1016\/j.clinthera.2024.11.015_bib0036","doi-asserted-by":"crossref","first-page":"951099","DOI":"10.3389\/fendo.2023.951099","article-title":"Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors","volume":"14","author":"Pruett","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/j.clinthera.2024.11.015_bib0071","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12978-024-01758-5","article-title":"Ranking the dietary interventions by their effectiveness in the management of polycystic ovary syndrome: a systematic review and network meta-analysis","volume":"21","author":"Juh\u00e1sz","year":"2024","journal-title":"Reprod Health"},{"issue":"1","key":"10.1016\/j.clinthera.2024.11.015_bib72","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12020-023-03487-4","article-title":"Effects and plasma proteomic analysis of GLP-1RA versus CPA\/EE, in combination with metformin, on overweight PCOS women: a randomized controlled trial","volume":"83","author":"Liao","year":"2023","journal-title":"Endocrine"},{"issue":"3","key":"10.1016\/j.clinthera.2024.11.015_bib73","article-title":"Effectiveness of high-intensity interval training for weight loss in adults with obesity: a randomised controlled non-inferiority trial","volume":"7","author":"D\u2019Amuri","year":"2021","journal-title":"BMJ Open Sport Exerc Med"},{"issue":"Supplement_1","key":"10.1016\/j.clinthera.2024.11.015_bib74","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvad114.1549","article-title":"THU645 Comparison Of LC-MS\/MS Testosterone Assays Towards Standardization Of Lower Testosterone Ranges","volume":"7","author":"Cree","year":"2023","journal-title":"J Endocr Soc"},{"issue":"1","key":"10.1016\/j.clinthera.2024.11.015_bib75","doi-asserted-by":"crossref","first-page":"32","DOI":"10.33808\/clinexphealthsci.769735","article-title":"Evaluation of Sexual Functions in Women Using Hormonal or Non-Hormonal Contraceptives","volume":"12","author":"TOPSAKAL","year":"2022","journal-title":"Clin Exp Heal Sci"},{"issue":"2","key":"10.1016\/j.clinthera.2024.11.015_bib0054","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3390\/life12020308","article-title":"Effectiveness of lifestyle modification in polycystic ovary syndrome patients with obesity: a systematic review and meta-analysis","volume":"12","author":"Kim","year":"2022","journal-title":"Life"},{"issue":"1","key":"10.1016\/j.clinthera.2024.11.015_bib76","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1210\/jc.2014-2956","article-title":"Relationship between 17-Hydroxyprogesterone responses to human chorionic gonadotropin and markers of ovarian follicle morphology in women with polycystic ovary syndrome","volume":"100","author":"Maas","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"03","key":"10.1016\/j.clinthera.2024.11.015_bib0013","first-page":"84","article-title":"Metformin effects on polycystic ovarian syndrome","volume":"6","author":"Barrouq","year":"2023","journal-title":"East African Sch J Med Sci"},{"issue":"2","key":"10.1016\/j.clinthera.2024.11.015_bib0014","doi-asserted-by":"crossref","first-page":"994","DOI":"10.53350\/pjmhs22162994","article-title":"Efficacy of metformin therapy in management of polycystic ovary syndrome","volume":"16","author":"Fatima","year":"2022","journal-title":"Pakistan J Med Heal Sci"},{"key":"10.1016\/j.clinthera.2024.11.015_bib0015","first-page":"9","article-title":"Role of metformin in the management of polycystic ovarian syndrome-associated acne: a systematic review","volume":"14","author":"Shamim","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.clinthera.2024.11.015_bib0016","doi-asserted-by":"crossref","DOI":"10.1177\/20420188221127142","article-title":"Impact of metformin on the clinical and metabolic parameters of women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials","volume":"13","author":"Abdalla","year":"2022","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.clinthera.2024.11.015_bib0017","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2022-002919","article-title":"Major malformations risk following early pregnancy exposure to metformin: a systematic review and meta-analysis","volume":"11","author":"Abolhassani","year":"2023","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.clinthera.2024.11.015_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jri.2022.103499","article-title":"Sitagliptin\/metformin improves the fertilization rate and embryo quality in polycystic ovary syndrome patients through increasing the expression of GDF9 and BMP15: a new alternative to metformin (a randomized trial)","volume":"150","author":"Daneshjou","year":"2022","journal-title":"J Reprod Immunol"},{"issue":"7","key":"10.1016\/j.clinthera.2024.11.015_bib0019","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.3390\/ijms19071954","article-title":"Metformin in pregnancy: mechanisms and clinical applications","volume":"19","author":"Hyer","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.clinthera.2024.11.015_bib0020","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/2042018810380215","article-title":"Review: role of metformin in the management of polycystic ovary syndrome","volume":"1","author":"Hany","year":"2010","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.clinthera.2024.11.015_bib0021","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.tem.2020.09.002","article-title":"Sitagliptin\/Metformin: a new medical treatment in polycystic ovary syndrome","volume":"31","author":"Daneshjou","year":"2020","journal-title":"Trends Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.clinthera.2024.11.015_bib0022","doi-asserted-by":"crossref","first-page":"23","DOI":"10.21518\/ms2023-156","article-title":"Metformin and sitagliptin fixed combination as the optimal choice in solving current problems in the type 2 diabetes mellitus treatment","volume":"17","author":"Biryukova","year":"2023","journal-title":"Meditsinskiy Sov = Med Counc"},{"issue":"4","key":"10.1016\/j.clinthera.2024.11.015_bib0023","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/dom.13940","article-title":"Effects of treatment with metformin and\/or sitagliptin on beta-cell function and insulin resistance in prediabetic women with previous gestational diabetes","volume":"22","author":"Daniele","year":"2020","journal-title":"Diabetes, Obes Metab"},{"issue":"12","key":"10.1016\/j.clinthera.2024.11.015_bib0024","doi-asserted-by":"crossref","first-page":"22","DOI":"10.9734\/jpri\/2023\/v35i127361","article-title":"Glucagon-like peptide 1 receptor agonists for the treatment of polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials","volume":"35","author":"Alshehri","year":"2023","journal-title":"J Pharm Res Int"},{"issue":"13","key":"10.1016\/j.clinthera.2024.11.015_bib0025","doi-asserted-by":"crossref","first-page":"10449","DOI":"10.3390\/ijms241310449","article-title":"Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials","volume":"24","author":"Popoviciu","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinthera.2024.11.015_bib0026","first-page":"1","article-title":"Potential roles of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in nondiabetic populations","volume":"2022","author":"Xu","year":"2022"},{"issue":"8","key":"10.1016\/j.clinthera.2024.11.015_bib0027","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.3390\/biomedicines10081989","article-title":"Therapeutic potential of glucagon-like peptide-1 agonists in polycystic ovary syndrome: from current clinical evidence to future perspectives","volume":"10","author":"Jensterle","year":"2022","journal-title":"Biomedicines"},{"issue":"7","key":"10.1016\/j.clinthera.2024.11.015_bib0028","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1210\/clinem\/dgad076","article-title":"GLP-1 receptor agonists and risk of adverse cerebrovascular outcomes in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"108","author":"Banerjee","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.clinthera.2024.11.015_bib0029","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.17219\/acem\/151695","article-title":"GLP-1 receptor agonists, polycystic ovary syndrome and reproductive dysfunction: current research and future horizons","volume":"31","author":"Papaetis","year":"2022","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.clinthera.2024.11.015_bib0030","article-title":"Effect of GLP-1 agonists on weight loss in patients with polycystic ovary syndrome and obesity: a single-center study","volume":"2","author":"Srinivasan","year":"2022","journal-title":"Obes Pillars"},{"issue":"10","key":"10.1016\/j.clinthera.2024.11.015_bib0032","doi-asserted-by":"crossref","DOI":"10.1111\/ijpo.12799","article-title":"Liraglutide pharmacokinetics and exposure-response in adolescents with obesity","volume":"16","author":"Carlsson Petri","year":"2021","journal-title":"Pediatr Obes"},{"issue":"1","key":"10.1016\/j.clinthera.2024.11.015_bib0033","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.15190\/d.2022.4","article-title":"Novel antidiabetic medications in polycystic ovary syndrome","volume":"10","author":"Somagutta","year":"2022","journal-title":"Discoveries"},{"issue":"6","key":"10.1016\/j.clinthera.2024.11.015_bib0034","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3682","article-title":"Cardiometabolic effects of SGLT2 inhibitors on polycystic ovary syndrome","volume":"39","author":"Lempesis","year":"2023","journal-title":"Diabetes Metab Res Rev"},{"issue":"4","key":"10.1016\/j.clinthera.2024.11.015_bib0035","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3390\/biomedicines11040998","article-title":"The potential of SGLT-2 inhibitors in the treatment of polycystic ovary syndrome: the current status and future perspectives","volume":"11","author":"Rakic","year":"2023","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.clinthera.2024.11.015_bib0037","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-058260","article-title":"Sodium-glucose cotransporter-2 inhibitors for improving endocrine and metabolic profiles in overweight and obese individuals with polycystic ovary syndrome: a meta-analysis protocol","volume":"12","author":"Zhang","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.clinthera.2024.11.015_bib0038","doi-asserted-by":"crossref","first-page":"830401","DOI":"10.3389\/fendo.2022.830401","article-title":"A meta-analysis of the effect of sodium glucose cotransporter-2 inhibitors on metabolic parameters in patients with polycystic ovary syndrome","volume":"13","author":"Sinha","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"10.1016\/j.clinthera.2024.11.015_bib0039","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1111\/dom.14495","article-title":"Licogliflozin versus placebo in women with polycystic ovary syndrome: a randomized, double-blind, phase 2 trial","volume":"23","author":"Tan","year":"2021","journal-title":"Diabetes, Obes Metab"},{"issue":"10","key":"10.1016\/j.clinthera.2024.11.015_bib0040","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1210\/clinem\/dgab408","article-title":"Exenatide, dapagliflozin, or phentermine\/topiramate differentially affect metabolic profiles in polycystic ovary syndrome","volume":"106","author":"Elkind-Hirsch","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.clinthera.2024.11.015_bib0041","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2174\/22123911MTA5pMzA20","article-title":"Efficacy and cardiovascular safety of DPP-4 inhibitors","volume":"16","author":"Subrahmanyan","year":"2021","journal-title":"Curr Drug Saf"},{"issue":"13","key":"10.1016\/j.clinthera.2024.11.015_bib0042","doi-asserted-by":"crossref","first-page":"7108","DOI":"10.1021\/acs.jmedchem.0c00374","article-title":"Design, synthesis, and evaluation of a series of novel super long-acting DPP-4 inhibitors for the treatment of type 2 diabetes","volume":"63","author":"Zhang","year":"2020","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.clinthera.2024.11.015_bib0043","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/ph14020144","article-title":"Novel potent and selective DPP-4 inhibitors: design, synthesis and molecular docking study of dihydropyrimidine phthalimide hybrids","volume":"14","author":"Mourad","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"40","key":"10.1016\/j.clinthera.2024.11.015_bib0044","doi-asserted-by":"crossref","first-page":"9598","DOI":"10.1039\/C6OB01818A","article-title":"Synthesis and biological evaluation of triazole based uracil derivatives as novel DPP-4 inhibitors","volume":"14","author":"Li","year":"2016","journal-title":"Org Biomol Chem"},{"issue":"1","key":"10.1016\/j.clinthera.2024.11.015_bib0045","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1210\/clinem\/dgz028","article-title":"Sitagliptin decreases visceral fat and blood glucose in women with polycystic ovarian syndrome","volume":"105","author":"Devin","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"15","key":"10.1016\/j.clinthera.2024.11.015_bib0046","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.3390\/ijerph16152720","article-title":"The role of DPP-4 inhibitors in the treatment algorithm of type 2 diabetes mellitus: when to select, what to expect","volume":"16","author":"Makrilakis","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.clinthera.2024.11.015_bib0047","first-page":"1","article-title":"Role of Metformin in polycystic ovary syndrome (PCOS): related infertility","volume":"15","author":"Attia","year":"2023","journal-title":"Cureus"},{"issue":"Supplement_1","key":"10.1016\/j.clinthera.2024.11.015_bib77","doi-asserted-by":"crossref","DOI":"10.1210\/js.2019-MON-474","article-title":"MON-474 Dipeptidyl Peptidase-4 (DPP4) inhibition decreases visceral fat and improves glucose metabolism in overweight women with polycystic ovarian syndrome","volume":"3","author":"Devin","year":"2019","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.clinthera.2024.11.015_bib78","article-title":"Insightful perspectives on Sodium-glucose Co-transporter 2 inhibitors: Navigating safety updates and beyond","volume":"16","author":"Panda","year":"2024","journal-title":"Curr Drug Res Rev"},{"issue":"3","key":"10.1016\/j.clinthera.2024.11.015_bib79","doi-asserted-by":"crossref","DOI":"10.23736\/S0026-4806.21.07085-3","article-title":"Liraglutide monotherapy and add on therapy on obese women with polycystic ovarian syndromes: a systematic review and meta-analysis","volume":"113","author":"TIAN","year":"2022","journal-title":"Minerva Med"},{"issue":"1","key":"10.1016\/j.clinthera.2024.11.015_bib80","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2337\/db23-0356","article-title":"Weight Loss\u2013Independent effect of liraglutide on insulin sensitivity in individuals with obesity and prediabetes","volume":"73","author":"Mashayekhi","year":"2024","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.clinthera.2024.11.015_bib0048","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1186\/s13063-022-06586-1","article-title":"A novel GnRH antagonist protocol based on LH levels versus traditional flexible GnRH antagonist protocol in PCOS patients undergoing in vitro fertilization: study protocol for a randomized controlled, non-inferiority trial","volume":"23","author":"Liu","year":"2022","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.clinthera.2024.11.015_bib0049","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1038\/s41598-022-08400-z","article-title":"Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF\/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis","volume":"12","author":"Kadoura","year":"2022","journal-title":"Sci Rep"},{"issue":"16","key":"10.1016\/j.clinthera.2024.11.015_bib0050","doi-asserted-by":"crossref","first-page":"4670","DOI":"10.3390\/jcm11164670","article-title":"Does serum LH level influence IVF outcomes in women with PCOS undergoing GnRH-antagonist stimulation: a novel indicator","volume":"11","author":"Wang","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.clinthera.2024.11.015_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104850","article-title":"Overactivation of GnRH neurons is sufficient to trigger polycystic ovary syndrome-like traits in female mice","volume":"97","author":"Silva","year":"2023","journal-title":"eBioMedicine"},{"issue":"12","key":"10.1016\/j.clinthera.2024.11.015_bib0052","doi-asserted-by":"crossref","first-page":"9815","DOI":"10.3390\/ijms24129815","article-title":"The thyroid hormone axis and female reproduction","volume":"24","author":"Brown","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.clinthera.2024.11.015_bib0053","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3390\/ijms23020583","article-title":"Polycystic ovary syndrome: a comprehensive review of pathogenesis, management, and drug repurposing","volume":"23","author":"Sadeghi","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.clinthera.2024.11.015_bib0055","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.3390\/healthcare10101999","article-title":"Acupuncture in women with human polycystic ovary\/ovarian syndrome: protocol for a randomized controlled trial","volume":"10","author":"de Oliveira","year":"2022","journal-title":"Healthcare"},{"issue":"9","key":"10.1016\/j.clinthera.2024.11.015_bib0056","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138793","article-title":"Effects of high intensity interval training and strength training on metabolic, cardiovascular and hormonal outcomes in women with polycystic ovary syndrome: a pilot study","volume":"10","author":"Almenning","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.clinthera.2024.11.015_bib0057","doi-asserted-by":"crossref","first-page":"82","DOI":"10.33545\/gynae.2023.v7.i1b.1256","article-title":"The effect of vitamin D3 supplementation in vitamin D3 deficient women with polycystic ovarian syndrome and it's relation to insulin resistance and visceral fat thickness","volume":"7","author":"Eldin","year":"2023","journal-title":"Int J Clin Obstet Gynaecol"},{"issue":"1","key":"10.1016\/j.clinthera.2024.11.015_bib0058","doi-asserted-by":"crossref","first-page":"e10753","DOI":"10.2196\/10753","article-title":"Role or Synergistic Interaction of Adenosine and Vitamin D3 Alongside High-Intensity Interval Training and Isocaloric Moderate Intensity Training on Metabolic Parameters: Protocol for an Experimental Study","volume":"8","author":"Mirghani","year":"2019","journal-title":"JMIR Res Protoc"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824003606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824003606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T14:48:27Z","timestamp":1738766907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824003606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0149291824003606"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.11.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent Advances in Individualized Clinical Strategies for Polycystic Ovary Syndrome: Evidence From Clinical Trials and Emerging Pharmacotherapies","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}